Navigation Links
ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Date:9/8/2008

Preclinical Pharmacokinetic Data to be Presented at the 7th International

Symposium on Uveitis in Germany

ZURICH, Switzerland, Sept. 8 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that the company has successfully completed its Phase I clinical study of the company's lead product candidate, ESBA105, in ophthalmic indications. In April 2008, ESBATech initiated the Phase I study designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. This trial was conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNF-alpha, and it is being developed initially for ophthalmic indications. Several additional clinical studies are in the preparation stages.

Manfred Zierhut, Professor in the Department of Ophthalmology at the University of Tuebingen in Germany, will present preclinical pharmacokinetic data on ESBA105 on Friday, September 12, 2008, at the 7th International Symposium on Uveitis in Constance, Germany. For more information on the symposium and on Prof. Zierhut's abstract, please visit http://www.iusg2008.org/.

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, commented, "The completion of this Phase I study with ESBA105 in ophthalmic indications marks a critical clinical milestone for the company. Recently, ESBATech secured CHF 23M (USD 22M) in an extended Series B venture financing round. This financing will fund further clinical studies with ESBA105 in ophthalmic indications, as well as build broad franchises in ophthalmology, rheumatology and respiratory diseases for ESBA105 and other antibody fragments. We look forward to announcing the results of this Phase I study and future clinical trials."

Peter Lichtlen, M.D., Ph.D., Hea
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ESBATechs Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
2. Immureboost Inc Announces a Change of Name to Fountain Healthy Aging Inc
3. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
4. MedQuist Announces Additions to Board of Directors
5. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
6. Martek Announces Third Quarter 2008 Financial Results
7. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
8. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
9. American Oriental Bioengineering Announces Participation in September Investor Conferences
10. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
11. Mindray Medical International Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Rancho BioSciences , the ... Omicsoft’s Array Suite with tranSMART . Scientists ... to send data in tranSMART to Array Suite for ... of tranSMART including the new 1.2 release. Array ... storage for the analysis of high dimensional quantification data, ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 “Rapid ... automation across the U.S., increasing unemployment, depressing American ... It is a Catch 22—we need automated ... this means fewer jobs,” says economist and corporate ... Pollina Corporate Top 10 Pro-Business States for 2014, ...
(Date:7/31/2014)... Miami, Fla. (PRWEB) July 31, 2014 The ... for distribution of its monthly news magazine, Kidney Cancer News. ... have a presence on a website maintained by an international ... noted an immediate increase in viewers.” , This month’s program ... of kidney tumors analyzed in a recent study. Kidney ...
(Date:7/30/2014)... Calif. , July 30, 2014 ... a biopharmaceutical company leading the discovery and development of ... report financial results and highlights for the quarter ended ... the U.S. financial markets close. Regulus ... August 6, 2014, at 5:00 pm Eastern Daylight Time ...
Breaking Biology Technology:Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 2ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 3ITRA Global Affiliate’s Pollina Corporate Top 10 Pro-Business States Minimize the Impact of Automation on Middle Class and Unemployment 4Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... 15 China Biopharma,Inc. (OTC Bulletin Board: CBPC) ... Technology Co., Ltd. ("Soonfast") has successfully,completed its trial ... has been approved in China for external use ... ("HSV"). Tests have shown,an inhibitory effect on the ...
... ADELAIDE, Australia, Oct. 15 Ellex Medical Lasers,Limited ... and manufacture of,ophthalmic laser and ultrasound systems, announced ... McGuinness to its board of directors to,underpin the ... and a capital raising in the past twelve ...
... Use of New PGD Technique to be Presented at ... Reproductive Medicine (ASRM) Annual Meeting -, - Improved ... for Spontaneous Pregnancies as well as PGD with In ... Oct. 15 Empire,Genomics, developing high throughput technologies that ...
Cached Biology Technology:Company's Partner Completes Trial Production of a New Antiviral Medicine 2Company's Partner Completes Trial Production of a New Antiviral Medicine 3John Marshall and Kevin McGuinness Appointed to Ellex Board 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD) 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD) 3
(Date:8/1/2014)... MELBOURNE, Fla. , Aug. 1, 2014  LiveScan Service Provider Binary ... providers, owner/operator team. As a result, Binary Biometrics will improve its mobile service ... into Volusia County and service several new cities such ... DeBary , DeLand , Deltona , ... Lake Helen , New Smyrna Beach , ...
(Date:8/1/2014)... a new study, including two Simon Fraser University ... representatives and policymakers must collaborate closely on minimizing ... development. Viorel Popescu and Maureen Ryan, David H. ... department, are among eight international co-authors of the ... and the Environment . , Shale gas development ...
(Date:7/31/2014)... natural-gas production from shale rock has increased by ... still do not fully understand the industry,s effects ... in the journal Frontiers in Ecology and ... to vastly outpace scientific examination, a team of ... including Princeton University, concluded that determining the environmental ...
Breaking Biology News(10 mins):Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 2Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris 3Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 2'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 3
... the possibility that daily vitamin D supplementation can reduce the ... will appear in the journal Pediatrics and has ... vitamin D supplementation decreased the risk of respiratory infections among ... the start of the study. "Our randomized controlled ...
... Algae are high on the genetic engineering agenda as ... subjected to independent studies of any environmental risks that ... two prominent researchers say. Writing in the August ... researchers argue that ecology experts should be among scientists ...
... In evaluating the bioactive compounds of Illinois blueberry ... compounds that inhibit enzymes responsible for carbohydrate absorption and ... help people with diabetes decrease their blood sugar. ... that would optimize the inhibition of the alpha-amylase and ...
Cached Biology News:Vitamin D supplementation can decrease risk of respiratory infections in children 2Vitamin D supplementation can decrease risk of respiratory infections in children 3Ecologist: Genetically engineered algae for biofuel pose potential risks that should be studied 2Ecologist: Genetically engineered algae for biofuel pose potential risks that should be studied 3Drink made from berry wine may provide tasty drug for diabetes 2
The HQ505, 20 OptiGreen filter for the Molecular Imager FX is a band pass filter used for detection of Cy2 and FITC with 532 nm excitation....
The filter 605DF50 for the Molecular Imager FX is a band pass filter for ethidium bromide, SYPRO Red, SYPRO Ruby, Alexa Fluor 532 and 546, and Cy3 dyes when using the 635 nm laser....
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
... APO-DIRECT is a single-step staining method for ... by flow cytometry. The kit contains all ... in cells including: positive and negative control ... and rinsing buffers for processing individual steps ...
Biology Products: